Introduction to the standard dosage of adagrasib (Krazati) and answers to frequently asked questions during its use

Adagrasib (Krazati) is a KRAS G12C inhibitor, mainly used to treat malignant tumors such as advanced or metastatic non-small cell lung cancer with KRAS G12C mutations. The standard dose is 600 mg twice daily. It is recommended to take it orally after meals to improve drug absorption and reduce gastrointestinal adverse reactions. During the medication process, you should strictly follow the doctor's instructions, take it on time, and avoid missing doses or increasing or decreasing the dosage on your own to avoid affecting the efficacy or causing adverse events.

During use, patients may experience some common adverse reactions, such as diarrhea, nausea, vomiting, loss of appetite, fatigue, and increased liver function indicators. Most side effects are mild to moderate and can usually be alleviated through symptomatic treatment, short-term medication adjustments, or dietary improvements. However, if severe diarrhea, persistent vomiting, obvious jaundice or rapid weight loss occurs, you should contact your doctor immediately and adjust the dose or suspend the medication if necessary. Doctors usually monitor liver function, routine blood tests, and imaging tests regularly during treatment to ensure the safe use of the drug.

In addition, there may be interactions between adagrasib and other drugs, especially when combined with strong CYP3A4 inhibitors or inducers, which may affect the metabolism and blood concentration of the drug, thereby affecting the efficacy or increasing the risk of toxicity. Therefore, before starting medication, patients should proactively inform their doctors of all prescription drugs, over-the-counter drugs and health care products they are using, and avoid taking combined medications on their own. You should also avoid eating large amounts of grapefruit or drinking grapefruit juice while taking the medicine to avoid affecting drug metabolism.

Overall, adagrasib can effectively inhibit tumor progression at standard doses, but safe use and management of adverse reactions are equally important. Patients should follow medical advice, return for regular follow-up visits, and cooperate with regular monitoring and doctor guidance to achieve therapeutic effects while minimizing drug risks.

Reference materials:https://www.drugs.com/